Crude Oil Down Over 1%; Henry Schein Earnings Top Views
Portfolio Pulse from Lisa Levin
U.S. stocks were higher with the Dow Jones gaining over 300 points. Henry Schein Inc reported better-than-expected Q2 earnings with sales of $3.10 billion, slightly missing the consensus of $3.11 billion. Vistagen Therapeutics, Tabula Rasa HealthCare, and Sequans Communications saw their shares rise after positive news. Sage Therapeutics, Tivic Health Systems, and Yellow Corporation saw their shares drop due to negative developments.
August 07, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics shares dropped after the FDA issued a Complete Response Letter for the New Drug Application.
Negative regulatory news often leads to a negative impact on the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 90
NEGATIVE IMPACT
Tivic Health Systems shares dropped after the company priced a public offering of shares.
Share offerings often lead to a negative impact on the company's stock price due to dilution.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Yellow Corporation shares fell after the company filed for bankruptcy and is closing the business.
Bankruptcy news often leads to a negative impact on the company's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Henry Schein reported better-than-expected Q2 earnings, slightly missing sales consensus.
Positive earnings generally lead to a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sequans Communications shares rose after Renesas Electronics announced it will acquire the company.
Acquisition news often leads to a positive impact on the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 90
POSITIVE IMPACT
Tabula Rasa HealthCare shares rose after the company reported better-than-expected Q2 financial results.
Positive financial results generally lead to a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Vistagen Therapeutics shares shot up after the company announced successful Phase 3 trial results.
Positive clinical trial results often lead to a positive impact on the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 90